|
UK Press Releases
- 07.31.08: 'Additional Listing' Amendment
- 07.29.08: Northwest Biotherapeutics issues shares of common stock
- 07.18.08: Northwest Biotherapeutics To present at Next Generation Vaccine Conference
- 06.17.08: Board Change
- 06.17.08: Annual Reports Available
- 05.16.08: Financial Results for the First Quarter Period Ended 31 March 2008
- 05.06.08: Northwest secures US$4.0 million in debt financing
- 04.16.08: Financial Results for the Year Ended 31 December 2007
- 02.20.08: Phase I and Phase I/II DCVax®-Brain Data Continues to show Significantly Improved Survival Rates for Brain Cancer Patients
- 02.11.08: Company files Updated Registration Statement with SEC
- 01.03.08: Company Reports Issuance of Stock Option Awards
- 12.27.07: Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax®-L at University of Pennsylvania
- 12.20.07: Lonza Withdraws Majority of Claims In Patent Lawsuit Against Northwest Biotherapeutics
- 12.18.07: Company files Updated registration Statement with SEC
- 12.18.07: Company files Information Statement with SEC
- 12.04.07: Company files Amendment to Annual Report with SEC
- 11.21.07: Company registers stock in 2007 Employee Stock Option Plan with SEC
- 11.15.07: Northwest Biotherapeutics Q3 loss widens as costs grow
- 10.31.07: Issue of Shares
- 10.30.07: Shareholding in Company
- 10.19.07: Holding(s) in Company
- 10.02.07: Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
- 08.17.07: Disclosure of information required by AIM Rule 26
- 08.01.07: Northwest Biotherapeutics Disputes Patent Infringement Claims
- 07.16.07: Northwest Biotherapeutics, Inc. Responds to Media Reports
- 07.09.07: World’s First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland
- 06.22.07: Successful £15 million Fundraising and First Day of Dealings on AIM
|
